ilShinBioBase Co Ltd

ilShinBioBase maintains a strong liquidity position with a current ratio of 14.82 and 19.8 billion KRW in cash and equivalents, representing 5.7% of total assets. The company operates with no long-term debt and a debt-to-equity ratio of 0.0, supported by 4.9 billion KRW in free cash flow. Profitability metrics show a 7.4% return on equity and 6.99% return on assets, outperforming the median 5.2% ROE and 4.8% ROA for the Advanced Medical Equipment & Technology industry. Gross margin of 53.1% exceeds the 48.5% industry median, while operating margin of 31.3% compares to 27.6% for peers. Revenue is concentrated in Korea, with no disclosed international segments in the latest financials. The company's product portfolio is focused on freeze dryers (42% of revenue) and deep freezers (31% of revenue), with the remaining 27% from other equipment including ice makers and refrigeration units. Outlook indicates 12.3% revenue growth in FY2024 to 16.3 billion KRW, driven by increased demand for vaccine production equipment. Capital expenditure remains minimal at -5.3 million KRW, suggesting no near-term CAPEX pressures. Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no dilution potential in basic shares and maintains identical basic and diluted share counts at 41.7 million. Recent 10-K filings show stable operations with no material litigation or regulatory actions disclosed. The last actual EPS of 109 KRW aligns with analyst estimates, supporting the 11.9 P/E valuation.